This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease. Kidney Week 2023 not only served as a platform for the latest news and updates in the field but also marked the final meeting of the year for practitioners in the specialty of nephrology.
Hypertension, Volume 80, Issue 12 , Page 2533-2543, December 1, 2023. BACKGROUND:Hypertension frequently accompanies chronic kidneydisease (CKD) as etiology and sequela. We defined CKD as a sustained estimated glomerular filtration rate value <60 mL/min per 1.73 m2or a urine albumin-to-creatinine ratio ≥30 mg/g.
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
Introduction:Blood pressure targets for the elderly are still controversial, there is a lack of certainty about the benefit and safety of targeting ≤ 130mmHg systolic bloodpressure. of patients had cardiovascular disease, 10.9% chronic kidneydisease. diabetes, and 15.5%
8th December 2023 Nothing can simply be ‘good enough’. Here, for example, plucked at random, is a reference to the latest NICE guidelines on the management of hypertension (high bloodpressure) in adults. In addition, there are links to formal risk assessment in cardiovascular disease. 2 Have I read the entire document.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionAtherosclerosis, the hardening and narrowing of the arteries, occurs due to the buildup of plaque on the inner walls of the arteries which can result in reduced blood flow to the organs and tissues.
Getty Images milla1cf Fri, 12/08/2023 - 08:17 December 8, 2023 — The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other leading medical associations, have issued a new guideline for preventing and optimally managing atrial fibrillation (AFib).
milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. Orchestra BioMed and Medtronic, Inc. vs. 14.3%).
Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its bloodpressure effects. Finerenone is already approved to reduce cardiovascular and kidneydisease risks in patients with type 2 diabetes-associated CKD, but not for HF. in the future.
11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 As of June 2023, the U.S. Accessed November 8, 2023. Accessed January 18, 2023. μ/L on 0.6
Based on these results, updated diabetes guidelines recommend that in T2D patients with atherosclerotic cardiovascular disease, we should use GLP-1 RAs, and in T2D patients with heart failure or chronic kidneydisease, we should use an SGLT-2 inhibitor after first-line therapy with lifestyle and metformin [25]. 18-21, 2023.
Published on November 30, 2023, in the Journal of the American College of Cardiology, these new guidelines are based on a comprehensive literature review from May 2022 to November 2022, and provide important recommendations to clinicians caring for patients with or at risk of developing cardiovascular disease (CVD). J Am Coll Cardiol.
This study assessed the real-world use of vericiguat.Material and methodsThis cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content